Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study:
- This report provides in-depth analysis of the global bone cancer drug market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bone cancer drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market
Detailed Segmentation:
- Global Bone Cancer Drug Market, By Type:
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Global Bone Cancer Drug Market, By Treatment Type:
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Global Bone Cancer Drug Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bone Cancer Drug Market, By Region:
- North America
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Type
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Treatment Type
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Surgery
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Advaxis, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- Hoffmann-La Roche Ltd
- Teva Pharmaceutical
“*” marked represents similar segmentation in other categories in the respective section.
